On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was 15.92% up from the session before settling in for the closing price of $6.03. A 52-week range for RXRX has been $5.60 – $15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 132.77% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 2.45%. With a float of $323.88 million, this company’s outstanding shares have now reached $390.76 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 17.12%, while institutional ownership is 57.84%. The most recent insider transaction that took place on Dec 11 ’24, was worth 112,182. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 15,000 for $7.75, making the entire transaction worth $116,324.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.91.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.66 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 18.44 million. That was better than the volume of 6.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 20.05%. Additionally, its Average True Range was 0.69.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 35.19%, which indicates a significant increase from 29.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 140.69% in the past 14 days, which was higher than the 86.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.77, while its 200-day Moving Average is $7.76. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $7.30. Second resistance stands at $7.61. The third major resistance level sits at $8.21. If the price goes on to break the first support level at $6.39, it is likely to go to the next support level at $5.79. The third support level lies at $5.48 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are 286,641K outstanding shares of the company, which has a market capitalization of 2.73 billion. As of now, sales total 44,580 K while income totals -328,070 K. Its latest quarter income was 26,080 K while its last quarter net income were -95,840 K.
